RA Capital Nexus Fund II, L.P. — SEC insider filings
SEC reporting owner CIK 1825376. 86 insider filings on record with FilingPulse; latest filed 2026-11-17.
Transaction summary — filings shown
Covers the 50 most recent of 86 filings on record, filed 2023-07-25 to 2026-11-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 34 legs across 17 filings — 55,389,583 shares, $403,546,341 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 1 filing — 3,525,094 shares, $3,807,102 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 83.
- Largest priced transaction: purchase of 1,200,000 shares @ $44.75 ($53,700,000) in Janux Therapeutics, Inc., filed 2024-10-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| PepGen Inc. (PEPG) | Director | 6 | 3 legs · 20,557,593 sh · $100,337,790 | — | 3 |
| Janux Therapeutics, Inc. (JANX) | Director | 6 | 5 legs · 2,024,041 sh · $79,042,965 | — | 7 |
| Hemab Therapeutics Holdings, Inc. (COAG) | Director | 1 | 6 legs · 2,840,429 sh · $52,222,946 | — | 9 |
| Climb Bio, Inc. (CLYM) | Director | 9 | 5 legs · 13,330,218 sh · $50,732,442 | — | 18 |
| ARS Pharmaceuticals, Inc. (SPRY) | Director | 6 | 6 legs · 7,851,299 sh · $44,722,936 | — | 3 |
| Acumen Pharmaceuticals, Inc. (ABOS) | Director | 5 | 1 leg · 5,161,290 sh · $39,999,998 | — | 6 |
| AN2 Therapeutics, Inc. (ANTX) | 10% owner | 2 | 1 leg · 1,777,778 sh · $16,000,002 | 2 legs · 3,525,094 sh · $3,807,102 | — |
| LENZ Therapeutics, Inc. (LENZ) | Director | 3 | 2 legs · 998,009 sh · $15,000,075 | — | 9 |
| Boundless Bio, Inc. (BOLD) | 10% owner | 1 | 2 legs · 312,500 sh · $5,000,000 | — | 6 |
| Werewolf Therapeutics, Inc. (HOWL) | Director, 10% owner | 2 | 3 legs · 536,426 sh · $487,188 | — | 1 |
+4 more issuers among the filings shown — every filing appears in the table below.
Insider filings — RA Capital Nexus Fund II, L.P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 4 | PepGen Inc. (PEPG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 8,625,000 @ $5 | EDGAR |
| 2026-09-30 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Option exercise (M): 10,000 @ $3.46 · Option exercise (M): 10,000 @ $3 · Option exercise (M): 10,000 @ $7.89 · Option exercise (M): 40,000 @ $1.29 · Option exercise (M): 10,000 (derivative) @ $0 · Option exercise (M): 10,000 (derivative) @ $0 · +2 more | EDGAR |
| 2026-07-22 | 4 | Freenome, Inc. (FRNM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 6,561,711 · Grant/award (A): 970,950 · Grant/award (A): 553,703 · Grant/award (A): 908,103 · Grant/award (A): 367,427 · Grant/award (A): 4,918,411 @ $10 · +1 more | EDGAR |
| 2026-07-01 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 70,284 (derivative) @ $0 | EDGAR |
| 2026-06-26 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | PepGen Inc. (PEPG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 5,500 @ $0 · Grant/award (A): 15,500 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2026-05-06 | 4 | Hemab Therapeutics Holdings, Inc. (COAG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund IV, L.P., Kolchinsky Peter, Shah Rajeev M. | Conversion (C): 3,607,846 · Conversion (C): 1,009,052 · Conversion (C): 221,188 · Purchase (P): 2,541,250 @ $18 · Purchase (P): 133,750 @ $18 · Purchase (P): 87,143 @ $24.59 · +9 more | EDGAR |
| 2026-04-29 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 2,106,000 (derivative) @ $9.50 | EDGAR |
| 2026-04-23 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 3,888,888 @ $1.80 | EDGAR |
| 2026-03-18 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 6,060,606 @ $3.30 | EDGAR |
| 2026-01-07 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 7,111 @ $3.50 | EDGAR |
| 2025-12-15 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Disposition to issuer (D): 20,440,000 @ $0 · Purchase (P): 213,099 @ $2.18 · Purchase (P): 101,462 @ $2.86 · Grant/award (A): 20,440,000 (derivative) | EDGAR |
| 2025-09-30 | 4 | PepGen Inc. (PEPG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 9,375,000 @ $3.20 | EDGAR |
| 2025-06-27 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 3,750 @ $0 · Grant/award (A): 11,667 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | PepGen Inc. (PEPG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Climb Bio, Inc. (CLYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 12,800 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 320,913 @ $0.86 · Purchase (P): 52,974 @ $0.98 · Purchase (P): 162,539 @ $0.98 | EDGAR |
| 2025-03-07 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 304,287 @ $30.56 · Purchase (P): 37,455 @ $31.30 · Purchase (P): 372,093 @ $30.78 · Purchase (P): 110,206 @ $31.02 | EDGAR |
| 2024-10-22 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 1,200,000 @ $44.75 | EDGAR |
| 2024-08-13 | 4 | AN2 Therapeutics, Inc. (ANTX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Sale (S): 3,410,335 @ $1.08 · Sale (S): 114,759 @ $1.08 | EDGAR |
| 2024-07-01 | 4 | Eliem Therapeutics, Inc. (ELYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 973,000 · Grant/award (A): 2,479,872 · Grant/award (A): 1,807,000 · Purchase (P): 11,949,171 @ $3.84 · Purchase (P): 1,059,375 @ $3.84 | EDGAR |
| 2024-06-28 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 2,500 @ $0 · Grant/award (A): 8,350 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Eliem Therapeutics, Inc. (ELYM) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | PepGen Inc. (PEPG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 17,500 (derivative) @ $0 | EDGAR |
| 2024-04-15 | 4 | Acrivon Therapeutics, Inc. (ACRV) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 3,530,000 @ $8.50 | EDGAR |
| 2024-04-04 | 4 | Boundless Bio, Inc. (BOLD) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Conversion (C): 1,587,912 · Purchase (P): 296,875 @ $16 · Conversion (C): 280,219 · Purchase (P): 15,625 @ $16 · Conversion (C): 17,000,000 (derivative) @ $0 · Conversion (C): 3,000,000 (derivative) @ $0 · +2 more | EDGAR |
| 2024-03-27 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 437,600 @ $9.06 · Purchase (P): 457,745 @ $9.55 · Purchase (P): 505,954 @ $9.79 | EDGAR |
| 2024-03-25 | 4 | LENZ Therapeutics, Inc. (LENZ) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Grant/award (A): 2,386,301 · Grant/award (A): 694,755 · Grant/award (A): 164,729 · Purchase (P): 933,038 @ $15.03 · Purchase (P): 64,971 @ $15.03 · Grant/award (A): 54,582 (derivative) · +3 more | EDGAR |
| 2024-03-06 | 4 | Janux Therapeutics, Inc. (JANX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 1,397,849 (derivative) @ $46.50 | EDGAR |
| 2024-02-20 | 4 | Icosavax, Inc. (ICVX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Code (U): 5,543 · Code (U): 5,324,897 · Code (U): 638,668 · Disposition to issuer (D): 22,278 (derivative) · Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2024-02-13 | 4 | PepGen Inc. (PEPG) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 2,557,593 @ $10.64 | EDGAR |
| 2023-09-25 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 2,508,691 @ $2.97 · Purchase (P): 191,309 @ $3.83 | EDGAR |
| 2023-08-31 | 4 | ARS Pharmaceuticals, Inc. (SPRY) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 3,750,000 @ $6.20 | EDGAR |
| 2023-08-22 | 4 | AN2 Therapeutics, Inc. (ANTX) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 1,777,778 @ $9 | EDGAR |
| 2023-08-09 | 4 | DICE Therapeutics, Inc. (DICE) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Code (U): 7,070,205 · Code (U): 786,407 · Disposition to issuer (D): 21,250 (derivative) | EDGAR |
| 2023-07-25 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) jointly with RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, Kolchinsky Peter, Shah Rajeev M. | Purchase (P): 5,161,290 @ $7.75 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1825376 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs